In a phase I trial, the antibody–drug conjugate datopotamab deruxtecan demonstrated encouraging response rates and manageable toxicity in patients with advanced/metastatic triple-negative breast cancer that has recurred after, or is resistant to, multiple therapies. Overall, 34% of patients experienced a complete or partial response.